These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 38973)

  • 21. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
    Bennett JP; Wooten GF
    Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations in dopamine receptors: effect of lesion and haloperidol treatment.
    Goldstein M; Lew JY; Asano T; Ueta K
    Commun Psychopharmacol; 1980; 4(1):21-5. PubMed ID: 6105037
    [No Abstract]   [Full Text] [Related]  

  • 23. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
    Bhargava HN
    Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of [3H]apomorphine to striatal membranes prepared from rat brain after 6-hydroxydopamine and kainic acid lesions.
    Fujita N; Saito K; Iwatsubo K; Hirata A; Noguchi Y; Yoshida H
    Brain Res; 1980 May; 190(2):593-6. PubMed ID: 7370810
    [No Abstract]   [Full Text] [Related]  

  • 25. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--II. Differential localization of dopamine and cholecystokinin receptors.
    Beresford IJ; Davenport AP; Sirinathsinghji DJ; Hall MD; Hill RG; Hughes J
    Neuroscience; 1988 Oct; 27(1):129-43. PubMed ID: 3264392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes of the striatal 3H-spiperone binding 3-6 weeks after nigrostriatal denervation and after two years.
    Guerin B; Silice C; Mouchet P; Feuerstein C; Demenge P
    Life Sci; 1985 Sep; 37(10):953-61. PubMed ID: 3162072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of timiperone on 3H-spiroperidol binding to rat striatal dopamine receptors.
    Tachizawa H; Sudo K; Sano M
    Eur J Pharmacol; 1979 Nov; 59(3-4):245-51. PubMed ID: 43256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of 3H-spiroperidol binding in rat striatum and frontal cortex by chronic amphetamine: dose response, time course and role of sustained dopamine release.
    Nielsen EB; Nielsen M; Braestrup C
    Psychopharmacology (Berl); 1983; 81(1):81-5. PubMed ID: 6415736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites.
    Coupet J; Rauh CE
    Eur J Pharmacol; 1979 Apr; 55(2):215-8. PubMed ID: 456420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral and biochemical evidence of apomorphine-induced supersensitivity of the striatal dopamine receptors.
    Deshaies P; Bédard P; Falardeau P; Di Paolo T
    Neuropharmacology; 1984 Oct; 23(10):1219-22. PubMed ID: 6521857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Occupation of dopamine receptors by N-n-propylnorapomorphine or spiperone and acetylcholine levels in the rat striatum.
    Korf J; Sebens JB; Flentge F; van der Werf JF
    J Neurochem; 1985 Jan; 44(1):314-8. PubMed ID: 3964835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guanine nucleotides do not inhibit tritiated dopamine agonist binding to bovine striatal membranes.
    Near JA; Mahler HR
    Neurochem Res; 1982 Jul; 7(7):831-7. PubMed ID: 7121724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Localization of [3H]N-propylnorapomorphine binding in mouse striatum.
    Severson JA; Randall PK
    Brain Res; 1983 Nov; 279(1-2):295-8. PubMed ID: 6416612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regional displacement by sulpiride of [3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors.
    Köhler C; Ogren SO; Haglund L; Angeby T
    Neurosci Lett; 1979 Jun; 13(1):51-6. PubMed ID: 572522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of alloxan-induced diabetes on dopaminergic receptors in rat striatum and anterior pituitary.
    Serri O; Renier G; Somma M
    Horm Res; 1985; 21(2):95-101. PubMed ID: 3979949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of chronic bromocriptine treatment on behaviour and dopamine receptor binding in the rat striatum.
    Traub M; Wagner HR; Hassan M; Jackson-Lewis V; Fahn S
    Eur J Pharmacol; 1985 Nov; 118(1-2):147-54. PubMed ID: 3936723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopaminergic component of [3H]spiroperidol binding in the rat anterior cerebral cortex.
    Marchais D; Tassin JP; Bockaert J
    Brain Res; 1980 Feb; 183(1):235-40. PubMed ID: 7357406
    [No Abstract]   [Full Text] [Related]  

  • 39. Chronic treatment with metoclopramide induces behavioral supersensitivity to apomorphine and enhances specific binding of 3H-spiroperidol to rat striata.
    Lautin A; Wazer D; Stanley M; Rotorsen J; Gershon S
    Life Sci; 1980 Jul; 27(4):305-16. PubMed ID: 7412477
    [No Abstract]   [Full Text] [Related]  

  • 40. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization.
    Hefti F; Melamed E; Wurtman RJ
    Brain Res; 1980 Aug; 195(1):123-37. PubMed ID: 6105003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.